Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases-Reference-Cited by-同舟云学术

Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases

Published:2019-04-30 Issue:1 Volume:10 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Guo Hui-Hui,Feng Chen-Lin,Zhang Wen-Xuan^ORCID,Luo Zhi-Gang,Zhang Hong-Juan,Zhang Ting-Ting,Ma Chen,Zhan Yun,Li Rui,Wu Song,Abliz Zeper,Li Cong,Li Xiao-Lin,Ma Xiao-Lei,Wang Lu-Lu,Zheng Wen-Sheng,Han Yan-Xing,Jiang Jian-Dong

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-019-09852-0.pdf

Reference55 articles.

1. Aron-Wisnewsky, J. & Clement, K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat. Rev. Nephrol. 12, 169–181 (2016).

2. Burnett, J. R. & Hooper, A. J. Running interference to lower cholesterol. Lancet 383, 10–12 (2014).

3. Affuso, F., Mercurio, V., Fazio, V. & Fazio, S. Cardiovascular and metabolic effects of Berberine. World J. Cardiol. 2, 71–77 (2010).

4. Catapano, A. L. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253, 281–344 (2016).

5. Kong, W. et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med 10, 1344–1351 (2004).

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancement of the stability and cytotoxicity of berberine by liposomal nanocarriers for gastric cancer treatment and its application in gummy candy;Frontiers in Gastroenterology;2024-08-29

2. Combining Multiple Omics with Molecular Dynamics Reveals SCP2-Mediated Cytotoxicity Effects of Aflatoxin B1 in SW480 Cells;Toxins;2024-08-24

3. Animal-based evidence supports the influence of biogenic silver and gold nanomaterials on the serum lipid profile: A novel approach in antihyperlipidemia management;Results in Surfaces and Interfaces;2024-08

4. Co-morbid intersections of cancer and cardiovascular disease and targets for natural drug action: Reprogramming of lipid metabolism;Biomedicine & Pharmacotherapy;2024-07

5. Nanozyme as a rising star for metabolic disease management;Journal of Nanobiotechnology;2024-05-06